Your browser is no longer supported. Please, upgrade your browser.
NVS Novartis AG daily Stock Chart
NVS [NYSE]
Novartis AG
Index- P/E29.64 EPS (ttm)2.91 Insider Own9.30% Shs Outstand2.58B Perf Week-3.88%
Market Cap221.88B Forward P/E15.15 EPS next Y5.69 Insider Trans-0.71% Shs Float2.51B Perf Month-2.75%
Income6.79B PEG3.57 EPS next Q1.33 Inst Own11.50% Short Float0.12% Perf Quarter-4.03%
Sales50.21B P/S4.42 EPS this Y66.90% Inst Trans-4.72% Short Ratio1.62 Perf Half Y3.22%
Book/sh22.26 P/B3.87 EPS next Y10.56% ROA8.40% Target Price101.00 Perf Year12.74%
Cash/sh4.01 P/C21.47 EPS next 5Y8.31% ROE17.80% 52W Range73.17 - 95.00 Perf YTD12.07%
Dividend2.83 P/FCF45.51 EPS past 5Y7.70% ROI11.50% 52W High-9.33% Beta0.60
Dividend %3.29% Quick Ratio0.70 Sales past 5Y0.20% Gross Margin70.10% 52W Low17.72% ATR1.28
Employees108000 Current Ratio0.90 Sales Q/Q3.40% Oper. Margin16.20% RSI (14)31.99 Volatility1.26% 1.04%
OptionableYes Debt/Eq0.59 EPS Q/Q-72.60% Profit Margin22.70% Rel Volume0.59 Prev Close86.99
ShortableYes LT Debt/Eq0.43 EarningsOct 17 BMO Payout59.60% Avg Volume1.90M Price86.14
Recom1.50 SMA20-3.40% SMA50-4.66% SMA2002.45% Volume1,153,108 Change-0.98%
Apr-25-19Upgrade Liberum Hold → Buy
Apr-25-19Upgrade Guggenheim Neutral → Buy
Apr-10-19Downgrade Morgan Stanley Equal-Weight → Underweight
Jan-02-19Downgrade JP Morgan Neutral → Underweight
Dec-11-18Resumed Jefferies Buy
Oct-09-18Initiated Guggenheim Neutral
Sep-10-18Upgrade BofA/Merrill Underperform → Buy
May-29-18Downgrade HSBC Securities Buy → Hold
May-25-18Upgrade Credit Suisse Underperform → Neutral
Jan-25-18Reiterated Leerink Partners Outperform $93 → $100
Dec-06-17Downgrade BofA/Merrill Neutral → Underperform
Jul-26-17Upgrade Morgan Stanley Underweight → Overweight
Jul-05-17Downgrade Credit Suisse Neutral → Underperform
Mar-09-17Initiated Liberum Buy
Mar-08-17Upgrade Societe Generale Hold → Buy
Mar-07-17Downgrade Exane BNP Paribas Neutral → Underperform
Jan-11-17Downgrade Credit Suisse Outperform → Neutral
Nov-10-16Upgrade Argus Hold → Buy
Oct-10-16Reiterated Chardan Capital Markets Buy $95 → $92
Sep-20-16Initiated Chardan Capital Markets Buy $95
Sep-16-19 10:16AM  Biogen Stops Late-Stage Studies on Alzheimer's Candidate Zacks
08:33AM  Breast Cancer Drugs May Inflame Lungs Per FDA Safety Alert Zacks
Sep-14-19 06:31AM  3 Biotech Stocks That Show The Good, The Bad and the Ugly Side of This Sector InvestorPlace
Sep-13-19 10:15AM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Certain Officers and Directors of Novartis AG GlobeNewswire
10:06AM  Adverum Reports Data From Phase I Wet AMD Study, Stock Down Zacks
06:21AM  Penn, Novartis end 7-year R&D alliance, will narrow scope of collaboration American City Business Journals
Sep-12-19 10:13AM  Puma Biotech's sNDA for Nerlynx Combo Gets FDA Acceptance Zacks
09:41AM  J&J's Ponesimod Superior to Aubagio in Relapsing MS Patients Zacks
09:30AM  Has Novartis (NVS) Outpaced Other Medical Stocks This Year? Zacks
Sep-11-19 04:30PM  Glancy Prongay & Murray LLP Continues its Investigation on Behalf of Novartis AG Investors (NVS) GlobeNewswire
03:50PM  Leaner Pfizer Positioned to Boost R&D Output GuruFocus.com
02:03PM  Pharma Stock Calls Could Double Fast Schaeffer's Investment Research
01:44PM  INVESTOR ALERT: Law Offices of Howard G. Smith Continues its Investigation on Behalf of Novartis AG Investors (NVS) GlobeNewswire
09:32AM  4 Big Drugmakers Boasting Impressive Oncology Pipelines Zacks
09:28AM  ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Novartis AG and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm GlobeNewswire
06:01AM  Allergan's Filings for Abicipar Pegol Accepted in U.S/Europe Zacks
Sep-10-19 06:45PM  NATIONALLY RANKED ROSEN LAW FIRM Continues To Investigate Securities Claims Against Novartis AG; ENCOURAGES INVESTORS WITH LOSSES IN EXCESS OF $100K TO CONTACT THE FIRM   NVS Business Wire
Sep-09-19 12:58PM  This Rockville biotech has added another deal to its growth plan American City Business Journals
11:21AM  Novartis Announces Positive Long-Term Data on Migraine Drug Zacks
09:31AM  UPDATE 1-Novartis CEO promises to speed data integrity disclosures Reuters
08:26AM  Novartis CEO pledges to speed data integrity disclosures Reuters
Sep-07-19 10:00AM  ROSEN, A LEADING LAW FIRM, Continues To Investigate Securities Claims Against Novartis AG NVS Business Wire
Sep-06-19 11:57AM  Pfizer is a Top Drugmaker: Is it the Right Time to Buy It? Zacks
11:53AM  FDA Grants Priority Review to Global Blood's SCD Candidate Zacks
11:48AM  Novartis' Capmatinib Gets Breakthrough Therapy Tag From FDA Zacks
11:36AM  Pharma Stock Roundup: AGN's Opioid Settlement, Line Extension Nod in EU for MRK, JNJ Drugs Zacks
02:24AM  UPDATE 1-Novartis joins Pfizer with FDA fast-track tag for lung cancer hopeful Reuters
Sep-05-19 05:00PM  ROSEN, A TOP RANKED LAW FIRM, Continues To Investigate Securities Claims Against Novartis AG NVS GlobeNewswire
01:50PM  AstraZeneca's Tagrisso Gets Nod in China for First-Line NSCLC Zacks
07:01AM  Novartis signs $840M pact with IFM Due amid fallout from AveXis deal American City Business Journals
Sep-04-19 02:10PM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Certain Officers and Directors of Novartis AG GlobeNewswire
11:30AM  ONGOING INVESTIGATION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Novartis AG and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm GlobeNewswire
10:40AM  Why Novartis (NVS) Stock Might be a Great Pick Zacks
09:37AM  Novartis Inks Commercialization Deal for Tysabri Biosimilar Zacks
Sep-03-19 07:01PM  UK cost watchdog recommends Novartis' blindness therapy Luxturna Reuters
09:06AM  Vertex snaps up Cambridge diabetes startup Semma for $950M American City Business Journals
08:45AM  Global Blood Focuses on Lead Candidate Amid Competition Zacks
07:02AM  5 Cancer-Fighting Stocks to Add to Your Portfolio Zacks
04:42AM  UPDATE 1-Novartis, Lonza deepen biosimilars push with MS, arthritis drug deals Reuters
01:52AM  Novartis's Sandoz licenses proposed multiple sclerosis biosimilar Reuters
Sep-02-19 07:51AM  Here's Why Glaxo (GSK) Steadily Stays Ahead of Its Industry Zacks
04:56AM  China expands drug bulk-buy programme, puts pressure on pharma firms Reuters
Aug-30-19 01:37PM  Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Novartis AG (NVS) ACCESSWIRE
11:16AM  AstraZeneca's Lupus Drug Meets Primary Endpoint in Study Zacks
10:11AM  Pharma Stock Roundup: JNJ's Opioid Lawsuit, Regulatory Nod for LLY, BMY, RHHBY Drugs Zacks
08:28AM  The Daily Biotech Pulse: Genmab-Novartis Multiple Sclerosis Drug Aces Late-Stage Studies, Akari Nets Orphan Drug Designation Benzinga
08:04AM  Novartis' (NVS) MS Drug Achieves Goals in Late-Stage Studies Zacks
05:40AM  Novartis takes aim at Roche's star MS drug Reuters
02:17AM  UPDATE 2-Novartis takes aim at Roche's star MS drug Reuters
Aug-29-19 06:25PM  IMPORTANT SHAREHOLDER NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Novartis AG and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm ACCESSWIRE
11:52AM  EQUITY ALERT: Rosen Law Firm Continues To Investigate Securities Claims Against Novartis AG NVS GlobeNewswire
11:24AM  Roche's Tecentriq Combo Gets EU Nod for Critical Breast Cancer Zacks
09:06AM  Forget Pfizer, Add These Big Drugmakers to Your Portfolio Zacks
Aug-28-19 04:13PM  J&J (JNJ) Loses Landmark Opioid Case: What's Next for Pharmaceuticals? Zacks
02:15PM  Ionis (IONS) Out-licenses Hepatitis B Virus Program to Glaxo Zacks
10:21AM  AstraZeneca's Fasenra Gets Orphan Drug Status for New Disease Zacks
Aug-27-19 11:36AM  Lilly's (LLY) Taltz Gets FDA Nod for Ankylosing Spondylitis Zacks
10:05AM  Amgen to Buy Celgene's Otezla: 5 ETF Drugs Zacks
09:30AM  Has Novartis (NVS) Outpaced Other Medical Stocks This Year? Zacks
Aug-26-19 10:30AM  Lilly's Olumiant Meets Primary Endpoint in 3rd Eczema Study Zacks
Aug-25-19 02:22PM  NVS LOSS NOTICE: Rosen, a Globally Recognized Law Firm, Announces Investigates Securities Claims Against Novartis AG - NVS ACCESSWIRE
Aug-22-19 02:37PM  Novo Nordisk's Fiasp Gets EC Approval for Label Expansion Zacks
Aug-21-19 03:23PM  David Rolfe Adds 4 Stocks to Portfolio in 2nd Quarter GuruFocus.com
11:50AM  ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Novartis AG and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm GlobeNewswire
11:04AM  Teva Launches Generic Version of Mylan's EpiPen for KIds Zacks
10:49AM  Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Novartis AG (NVS) ACCESSWIRE
Aug-20-19 04:00PM  Glancy Prongay & Murray LLP Continues its Investigation on Behalf of Novartis AG Investors (NVS) Business Wire
03:06PM  INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Novartis AG and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm Business Wire
01:42PM  INVESTOR ALERT: Law Offices of Howard G. Smith Continues its Investigation on Behalf of Novartis AG Investors (NVS) Business Wire
Aug-19-19 06:09PM  INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Novartis AG and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm Business Wire
03:58PM  EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Novartis AG NVS Business Wire
02:21PM  5 Companies Still Run by Families Motley Fool
08:04AM  AbbVie's JAK Inhibitor Rinvoq Receives FDA Approval for RA Zacks
06:00AM  5 Biggest New Drug Approvals Potentially on the Way in 2019 Motley Fool
03:20AM  Novartis to answer U.S. Senate demand for data manipulation details Reuters
01:00AM  Novartis executive sold almost $1m shares ahead of FDA probe Financial Times
Aug-18-19 12:18PM  Novartis executive sold shares before drug data manipulation made public Reuters
11:27AM  Novartis exec sold shares before drug data manipulation made public Reuters
Aug-16-19 01:10PM  A Breach of Trust? Here's Why the FDA's Taking Aim at Novartis' AveXis Motley Fool
10:33AM  AstraZeneca Calquence Gets FDA's Breakthrough Status for CLL Zacks
06:20AM  Gene therapies to test FDA's approach to regulating drugs after launch, experts say American City Business Journals
Aug-15-19 05:27PM  Frozen assets: How a startup wants to cryobank your cells to fight cancer in the future American City Business Journals
09:17AM  Epizyme (EPZM) Focuses on Developing Lead Drug Tazemetostat Zacks
Aug-14-19 11:27PM  Novartis replaces top scientists at Avexis after drug data manipulated Reuters
08:57PM  PRESS DIGEST- Financial Times - Aug 15 Reuters
03:00PM  Novartis Reportedly Fires Brothers For Manipulating Gene Therapy Data Investor's Business Daily
11:09AM  UPDATE 2-Novartis replaces top scientists at Avexis after drug data manipulated Reuters
10:58AM  Everyones Mad At Novartis. But the Stock Is Doing Just Fine Barrons.com
10:34AM  Novartis replaces top scientists at Avexis after drug data manipulated Reuters
09:37AM  Deciphera's GIST Drug Succeeds in Pivotal Study, Stock Up 80% Zacks
09:36AM  Wednesdays Vital Data: Amgen, American Airlines and Apple InvestorPlace
09:24AM  Lilly's Taltz Outshines J&J's Tremfya in Psoriasis Study Zacks
08:54AM  Novartis names Bulto as new head of U.S. drugs business Reuters
07:37AM  Novartis ousted scientists before reporting drug data manipulation Financial Times
Aug-13-19 04:45PM  Why This IBD Stock Of The Day Is No Longer Sweating $5 Billion In Sales Investor's Business Daily
11:12AM  Jazz (JAZZ) Acquires Cavion, Adds Movement Disorder Candidate Zacks
10:48AM  Here's Why Amgen Stock is Outperforming Its Industry Of Late Zacks
06:00AM  5 Biggest New Drugs Approved in 2019 So Far Motley Fool
Aug-12-19 06:05PM  UPDATE 1-Senator Grassley seeks info on Novartis's Zolgensma data issues Reuters
05:27PM  Senator Grassley seeks info on Novartis's Zolgensma data issues Reuters
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company's Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, cardio-metabolic, and established medicine products. The company's Sandoz segment provides active ingredients and finished dosage forms of pharmaceuticals in cardiovascular, central nervous system, dermatology, gastrointestinal and hormonal therapy, metabolism, oncology, ophthalmic, pain, and respiratory areas; and finished dosage form anti-infective. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products; and biotechnology manufacturing services. The company's Alcon segment offers intraocular lenses and equipment for cataract procedures; equipment, instruments, and devices for vitreoretinal surgeries; surgical equipment and diagnostic devices for refractive surgical procedures; and devices to treat glaucoma. It also provides viscoelastics, surgical solutions, diagnostic ophthalmic products, surgical packs, and other disposable products for cataract and vitreoretinal surgery. In addition, this segment offers contact lenses and ocular health products; over-the-counter ophthalmic products; eye drops for the temporary relief of ocular itching due to allergies; vitamins for ocular health; and iLux Device, a therapeutic device used to treat meibomian gland dysfunction. Novartis AG has collaboration agreements with Xencor; Surface Oncology; Ligand Pharmaceuticals, Inc.; Amgen; University of California, Berkeley; Bristol-Myers Squibb; IBM Watson Health; Allergan plc; Science 37, Inc.; Bill & Melinda Gates Foundation; PEAR Therapeutics; Pfizer; Conatus Pharmaceuticals Inc.; TRIO; Verily; and Pharming Group N.V. The company was founded in 1895 and is headquartered in Basel, Switzerland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Novartis Bioventures Ltd10% OwnerMay 28Buy14.00168,6302,360,8201,769,641May 30 09:27 PM
Novartis Bioventures Ltd10% OwnerApr 26Sale1.03138,704142,8654,049,804Apr 29 05:23 PM
Novartis Bioventures Ltd10% OwnerApr 25Sale1.03563,096579,9894,188,508Apr 29 05:23 PM
Novartis Bioventures Ltd10% OwnerApr 24Sale1.0316,40316,8954,751,604Apr 24 07:03 PM
Novartis Bioventures Ltd10% OwnerApr 23Sale1.0327,55428,3814,768,007Apr 24 07:03 PM
Novartis Bioventures Ltd10% OwnerApr 22Sale0.977,1006,8874,795,561Apr 24 07:03 PM
Novartis Bioventures Ltd10% OwnerApr 15Sale0.9928,79428,5064,802,661Apr 15 09:26 PM
Novartis Bioventures Ltd10% OwnerApr 12Sale1.0430,90832,1444,831,455Apr 15 09:26 PM
Novartis Bioventures Ltd10% OwnerApr 11Sale1.0857,43862,0334,862,363Apr 15 09:26 PM
Novartis Bioventures Ltd10% OwnerApr 10Sale1.09140,230152,8514,919,801Apr 10 06:26 PM
Novartis Bioventures Ltd10% OwnerApr 09Sale1.0132,99133,3215,060,031Apr 10 06:26 PM
Novartis Bioventures Ltd10% OwnerApr 08Sale1.0227,52528,0765,093,022Apr 10 06:26 PM
Novartis Bioventures Ltd10% OwnerApr 05Sale1.0224,66125,1545,120,547Apr 05 05:14 PM
Novartis Bioventures Ltd10% OwnerApr 04Sale1.0147,90048,3795,145,208Apr 05 05:14 PM
Novartis Bioventures Ltd10% OwnerApr 03Sale0.9658,03355,7125,193,108Apr 05 05:14 PM
Novartis Bioventures Ltd10% OwnerApr 02Sale0.9751,75450,2015,251,141Apr 02 08:09 PM
Novartis Bioventures Ltd10% OwnerApr 01Sale0.95116,909111,0645,302,895Apr 02 08:09 PM
Novartis Bioventures Ltd10% OwnerApr 01Sale1.9020,61039,1592,079,394Apr 02 08:23 PM
Novartis Bioventures Ltd10% OwnerMar 29Sale1.85106,540197,0992,100,004Apr 02 08:23 PM
Novartis Bioventures Ltd10% OwnerMar 29Sale0.9163,10057,4215,419,804Apr 02 08:09 PM
Novartis Bioventures Ltd10% OwnerMar 28Sale0.9488,83583,5055,482,904Mar 28 05:16 PM
Novartis Bioventures Ltd10% OwnerMar 27Sale0.9950,74950,2425,571,739Mar 28 05:16 PM
Novartis Bioventures Ltd10% OwnerMar 26Sale1.01177,762179,5405,622,488Mar 28 05:16 PM
Novartis Bioventures Ltd10% OwnerMar 15Sale1.9243,80084,0962,206,544Mar 15 05:25 PM
Novartis Bioventures Ltd10% OwnerMar 14Sale1.8813,80025,9442,250,344Mar 15 05:25 PM
Novartis Bioventures Ltd10% OwnerMar 13Sale2.12132,738281,4052,264,144Mar 15 05:25 PM